Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Pryatel

Psychiatry Grand Forks, ND Medical Doctor

NPI 1184760902 CMS profile 710689

1200 S. Columbia Rd, Grand Forks, ND 58201

Open in the dashboard

General payments

$1,690

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Pryatel of Grand Forks, ND is reported in the CMS Open Payments database as having received $1,690 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $235 14
2024 General $329 18
2023 General $386 23
2022 General $285 19
2020 General $158 8
2019 General $298 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Pryatel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to William Pryatel were reported at $235. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year William Pryatel Psychiatry median Middle half National median
2019 $298 $184 $59–$605 $163
2020 $158 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $285 $153 $50–$590 $149
2023 $386 $170 $56–$651 $160
2024 $329 $179 $57–$673 $164
2025 $235 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $332 22 payments
  2. Otsuka America Pharmaceutical, Inc. $298 19 payments
  3. Alkermes, Inc. $258 15 payments
  4. Janssen Pharmaceuticals, Inc $257 17 payments
  5. Teva Pharmaceuticals USA, Inc. $238 13 payments
  6. Allergan Inc. $119 5 payments
  7. Sunovion Pharmaceuticals Inc. $75 3 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $39 2 payments
  9. Axsome Therapeutics, Inc. $24 1 payment
  10. ITI, Inc. $19 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,690 100 payments
Products named General payments · program years 2019–2025
  1. INGREZZA $259 16 payments
  2. ARISTADA Cns $258 15 payments
  3. ARISTADA Cns $258 15 payments
  4. INVEGA SUSTENNA $257 17 payments
  5. ARISTADA Cns $242 14 payments
  6. ARISTADA Cns $242 14 payments
  7. UZEDY $176 9 payments
  8. ABILIFY MAINTENA $158 11 payments
  9. ABILIFY ASIMTUFII $142 8 payments
  10. LYBALVI $140 8 payments
  11. Other $624 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Psychiatry: 574

Drug cost

$490

Median for Psychiatry: $27,624

Branded share of claims

100%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 12 $490

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$1,000

Medicare's payments for the services billed

Medicare patients

12

Average age 49

Services billed

22

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $90
$90 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $71
$71 — —
ARISTADA
  • Alkermes, Inc. $47
$47 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $38
$38 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record